Trial Profile
A Randomized Active-Control Double-Blinded Study to Evaluate the Treatment of Diabetes in Patients With Systolic Heart Failure
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 22 Feb 2022
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms CANA-HF
- 04 Apr 2019 Status changed from active, no longer recruiting to completed.
- 08 Nov 2018 Planned End Date changed from 1 Nov 2018 to 1 Mar 2019.
- 08 Nov 2018 Status changed from recruiting to active, no longer recruiting.